In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price ...

Truist Financial analyst Jailendra Singh reiterated a Buy rating on IQVIA Holdings (IQV – Research Report) today and set a price target of ...

Clinical research company IQVIA (NYSE: IQV) in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand ...

Q4 2024 Earnings Call Transcript February 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3.12, ...

IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 12.3% in the 4th quarter, according to the company in its most recent ...

IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and ...

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Feb 6 (Reuters) - Contract research firm IQVIA Holdings (IQV.N), opens new tab beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand, the company’s full-year ...